Accelerate investment in breakthrough therapies that change the world
Prudentia Sciences Team
A team of experts, scientists, and technologists who have assessed assets, built companies, and seen how decisions actually get made.
Sadiqa Mahmood
CEO & Founder
Health Catalyst + Broad Institute of Harvard & MIT + Mass General Brigham
Sean O'Shea
CTO
Amwell + Fidelity + Betfair
John Reynders, PhD
Head of Strategy
Moderna + Alexion + J&J
Ben Klein
Head of Partnerships
Flatiron + Optum
Sharon Tan
Scientific Lead
Ultragenyx + enGene + Genzyme + Boston Scientific
Scientific Advisory Board
Scientific and clinical leaders ensuring every evaluation reflects how therapies are actually understood, developed, and advanced.
Mark Currie, PhD (SAB Chair)
Board Director, Ironwood Pharmaceuticals + Board Director, Science Exchange
Mary Lynne Hedley
Board Member, Eli Lilly and Veeva + Venture Partner, Third Rock Ventures + Co-founder and CSO of Tesaro (acquired by GSK)
Matt Leoni, MD
Chief Medical Officer, Merida Biosciences + SVP Global Clinical Development, Cerevel Therapeutics + Former SVP Global Clinical Development, Cerevel Therapeutics + Former Senior Director, CNS, Global Clinical Development
.png)
David Nicholson, PhD
Executive Vice President and Chief R&D Officer at Allergan + Chief Technology Officer and EVP, R&D at Bayer
Business Advisory Board
Operators and investors grounding Prudentia in how decisions get made: where science, capital, and deal dynamics meet.
Travis May
CEO, Shaper Capital + Co-Founder and CEO, Datavant ($7B M&A with Ciox) + Co-Founder and CEO, LiveRamp ($310M acquisition by Acxiom)
Joe Von Rickenbach
Senior Advisor, General Atlantic + Co-Founder, Chairman, CEO, Parexel + Co-Founder, CEO, Helio Vision, Inc.
Stuart Chafee
CEO, QuantX Biosciences + Co-Founder and Head of BD, Kymera Therapeutics (IPO) + CBO of Affinivax (acquired by GSK) + CBO & CFO, Praxis Precision Medicines (IPO)